The Phoenix Reporter

The Phoenix Reporter DEV

A Compendium of Insightful Information for Our Phoenix Community, Vol. 4 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New in […]

Read More
Topics:

Ready, Set, Model! Take PK/PD Analysis to New Heights with Phoenix 8.0

Maria Saluta

Dr. Scott Gottlieb, the Commissioner of Food and Drugs, has outlined the steps the US FDA will take to implement the 21st Century Cures Act. In outlining the plan, the Commissioner endorses modeling and simulation approaches to increase the efficiency of drug development. Certara has launched Phoenix® 8.0, the latest version of the innovative PK/PD […]

Read More
Topics: PK/PD Modeling & Simulation

The Phoenix Reporter

A Compendium of Insightful Information for Our Phoenix Community June 2018 Welcome to The Phoenix® Reporter. In this e-newsletter, we will share informative educational content along with practical, implementable resources with our Phoenix user community. This issue provides an overview of the new features and enhancements in Phoenix 8.1, the newest version of our PK/PD software: What’s New […]

Read More
Topics:

IVIVC Toolkit

Phoenix IVIVC Toolkit The Gold Standard for Predicting Pharmacokinetic (PK) Parameters from In Vitro Dissolution Data in Drug Development and Formulations. The Phoenix® IVIVC Toolkit™ creates and substantiates the Level A correlation as outlined in the FDA Guidance for Industry1 to correlate the in vitro dissolution profile of a dosage form with the in vivo pharmacokinetic (PK) […]

Read More
Topics:

PK/PD Analysis

PK/PD Support for Drug Approvals Pharmacometrics: From “nice to have” to “must have” technology Model informed drug development and discovery—which includes both top-down pharmacokinetic/pharmacodynamic (PK/PD) modeling and bottom-up, mechanistic approaches―continues to profoundly impact drug development by informing key decisions and labeling. Key benefits of this approach include: Making data-driven decisions at all stages of drug […]

Read More
Topics:

Pharmacometrics Regulatory Strategy

Predictive Disease-Drug-Trial Modeling and Simulation A well-designed pharmacometrics regulatory strategy satisfies multiple goals. First, the strategy prioritizes the needs of the program and details when and how they will be met. Next, a strategic road map provides direction that ensures that studies and analyses will be fit-for-purpose and add value to the program. Finally, a […]

Read More
Topics:

Contact Us

Sales Inquiries Interested in learning more? Please fill out the form and a representative will get back to you. Or, please contact us at any of our locations below: United States:  1-888-708-7444 or 1-919-852-4685 Germany:  +49 89 45 10 300 United Kingdom:  +44 (0) 114 460 0200 Australia:  +61 3 8610 6683 New Zealand:  +64 9 363 […]

Read More
Topics:

About Our Solutions

Cutting Edge Modeling and Simulation Solutions for Drug Development Drug development has become more complex and multi-layered. New combination therapies require more precise and individualized analyses, new approaches such as “basket studies” evaluate potential disease targets through a new lens, safety issues are more challenging, and comparative effectiveness plays an increasingly important role in “go/no […]

Read More
Topics:
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog